| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910148642203321 |
|
|
Autore |
Bowen Lila |
|
|
Titolo |
Conspiracy of ravens / / Lila Bowen |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
New York, New York : , : Orbit, , [2016] |
|
©2016 |
|
|
|
|
|
|
|
|
|
ISBN |
|
0-316-30226-0 |
0-316-26434-2 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (317 pages) |
|
|
|
|
|
|
Collana |
|
|
|
|
|
|
Classificazione |
|
FIC009030FIC024000FIC009050FIC002000FIC043000 |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Racially mixed people |
Quests (Expeditions) |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
Intro -- Title Page -- Welcome -- Also by Lila Bowen -- Dedication -- Map -- Chapter 1 -- Chapter 2 -- Chapter 3 -- Chapter 4 -- Chapter 5 -- Chapter 6 -- Chapter 7 -- Chapter 8 -- Chapter 9 -- Chapter 10 -- Chapter 11 -- Chapter 12 -- Chapter 13 -- Chapter 14 -- Chapter 15 -- Chapter 16 -- Chapter 17 -- Chapter 18 -- Chapter 19 -- Chapter 20 -- Chapter 21 -- Chapter 22 -- Chapter 23 -- Chapter 24 -- Chapter 25 -- Chapter 26 -- Chapter 27 -- Chapter 28 -- Author's Note -- Acknowledgments -- EXTRAS -- Meet The Author -- A Preview of "Malice of Crows -- A Preview of "The Fifth Season -- Praise for Lila Bowen -- Orbit Newsletter -- Table of Contents -- Copyright. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
"The sequel to Wake of Vultures, where a rich, secret world is hiding beneath the surface. Nettie Lonesome made a leap -- not knowing what she'd become. But now her destiny as the Shadow is calling. A powerful alchemist is leaving a trail of dead across the prairie. And Nettie must face the ultimate challenge: side with her friends and the badge on her chest or take off alone on a dangerous mission that is pulling her inexorably toward the fight of her life. When it comes to monsters and men, the world isn't black and white. What good are two wings and a gun when your enemy can command a conspiracy of ravens? The Shadow series; Wake of Vultures -- Conspiracy of Ravens"-- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2. |
Record Nr. |
UNINA9910557380603321 |
|
|
Autore |
Morabito Alessandro |
|
|
Titolo |
Small Cell Lung Cancer: A New Era Is Beginning? |
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021 |
|
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (150 p.) |
|
|
|
|
|
|
Soggetti |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Sommario/riassunto |
|
Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody-drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques. |
|
|
|
|
|
|
|
| |